Suppr超能文献

载姜醇酸和乙二醇多嵌段共聚物纳米粒作为环孢素 A 的口服给药载体:周期侧链羧酸基的影响

Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.

机构信息

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 0NR, UK.

出版信息

J R Soc Interface. 2010 Aug 6;7 Suppl 4(Suppl 4):S475-81. doi: 10.1098/rsif.2010.0046.focus. Epub 2010 May 26.

Abstract

The purpose of this study was to evaluate the potential of new carboxylated multi-block copolymer of lactic acid and ethylene glycol (EL14) for nanoparticle (NP) formation and their ability to deliver high molecular weight hydrophobic drug--cyclosporine A (CsA). CsA-loaded EL14 NPs were compared with traditional poly(lactide-co-glycolide) (PLGA) NPs, both prepared by emulsion-diffusion-evaporation process. On the one hand, the increase in drug payload from 10 to 30 per cent for EL14 NPs showed no difference in particle size, however the entrapment efficiency tends to decrease from 50 to 43 per cent; on the other hand, the more hydrophobic PLGA showed an increasing trend in entrapment efficiency from 20 to 62 per cent with increasing particle size. Over 90 per cent of CsA was released in vitro from both the nanoparticulates; however, the release was much slower in the case of more hydrophobic PLGA. On in vivo evaluation in rats, the NPs made of EL14 showed a higher C(max), a faster T(max) and enhanced tissue levels to that of PLGA that are crucial for CsA's activity and toxicity; however, the overall bioavailability of the nanoparticulates was similar and higher than Neoral. Together these data demonstrate the feasibility of NPs made of low molecular weight, hydrophilic polymer EL14 for efficient delivery of CsA.

摘要

本研究旨在评估新型羧基化聚乳酸-乙二醇共聚物(EL14)作为纳米颗粒(NP)形成的潜力及其递送高分子量疏水性药物环孢素 A(CsA)的能力。将载有 CsA 的 EL14 NPs 与通过乳液扩散蒸发法制备的传统聚乳酸-乙醇酸共聚物(PLGA) NPs 进行比较。一方面,EL14 NPs 的药物载量从 10%增加到 30%,粒径没有差异,但是包封效率从 50%下降到 43%;另一方面,疏水性更强的 PLGA 随着粒径的增加,包封效率呈上升趋势,从 20%增加到 62%。两种纳米颗粒体外释放超过 90%的 CsA;然而,疏水性更强的 PLGA 释放更慢。在大鼠体内评估中,EL14 制成的 NPs 显示出更高的 C(max)、更快的 T(max)和增强的组织水平,这对 CsA 的活性和毒性至关重要;然而,纳米颗粒的整体生物利用度与 Neoral 相似且更高。这些数据共同证明了低分子量亲水性聚合物 EL14 制成的 NPs 用于有效递送 CsA 的可行性。

相似文献

1
Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.
J R Soc Interface. 2010 Aug 6;7 Suppl 4(Suppl 4):S475-81. doi: 10.1098/rsif.2010.0046.focus. Epub 2010 May 26.
2
PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
J Control Release. 2007 Jun 4;119(2):197-206. doi: 10.1016/j.jconrel.2007.02.004. Epub 2007 Feb 14.
7
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
J Control Release. 2001 Apr 2;71(2):203-11. doi: 10.1016/s0168-3659(01)00218-8.
8
Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.
J Mater Sci Mater Med. 2006 Jun;17(6):509-16. doi: 10.1007/s10856-006-8933-3.
9
The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability.
Int J Nanomedicine. 2012;7:559-70. doi: 10.2147/IJN.S27641. Epub 2012 Feb 2.

引用本文的文献

1
Nanotechnological Approaches to Immunosuppression and Tolerance Induction.
Curr Transplant Rep. 2017 Jun;4(2):159-168. doi: 10.1007/s40472-017-0146-9. Epub 2017 Apr 17.
2
Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A.
J Transplant. 2012;2012:896141. doi: 10.1155/2012/896141. Epub 2012 Mar 29.
3
Scaling the heights--challenges in medical materials. Introduction.
J R Soc Interface. 2010 Aug 6;7 Suppl 4(Suppl 4):S377-8. doi: 10.1098/rsif.2010.0259.focus. Epub 2010 Jun 2.

本文引用的文献

1
Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10.
Nanotechnology. 2010 Feb 10;21(6):065104. doi: 10.1088/0957-4484/21/6/065104. Epub 2010 Jan 11.
2
Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
Exp Eye Res. 2008 Sep;87(3):162-7. doi: 10.1016/j.exer.2008.04.002. Epub 2008 Apr 12.
5
PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
J Control Release. 2007 Jun 4;119(2):197-206. doi: 10.1016/j.jconrel.2007.02.004. Epub 2007 Feb 14.
7
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
Drug Discov Today. 2006 Sep;11(17-18):846-54. doi: 10.1016/j.drudis.2006.07.015.
8
PLGA nanoparticles in drug delivery: the state of the art.
Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422. doi: 10.1615/critrevtherdrugcarriersyst.v21.i5.20.
9
Cyclosporine A and adverse effects on organs: histochemical studies.
Prog Histochem Cytochem. 2004;39(2):85-128. doi: 10.1016/j.proghi.2004.04.001.
10
pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
Int J Pharm. 2004 Aug 6;280(1-2):229-40. doi: 10.1016/j.ijpharm.2004.05.006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验